Deals

Betta Pharmaceuticals Acquires Global Rights to SS202 Ultra‑Long‑Acting Monthly Growth Hormone from Gensciences – Deal Valued at Up to RMB 50 Million Plus Royalties
Betta PharmaceuticalsGensciences

Betta Pharmaceuticals Acquires Global Rights to SS202 Ultra‑Long‑Acting Monthly Growth Hormone from Gensciences – Deal Valued at Up to RMB 50 Million Plus Royalties

Betta Pharmaceuticals Co., Ltd. (SHE: 300558) and Hangzhou Gensciences Biopharmaceuticals Co., Ltd. announced a collaboration under which Betta Pharmaceuticals has acquired the global exclusive rights to the ultra‑long‑acting monthly growth…

Astellas Inks Exclusive Option and License Deal for Audax's DAX-044 – Up to USD 1.3 Billion to Back Tumor-Targeted IL-12 Immunotherapy

Astellas Inks Exclusive Option and License Deal for Audax’s DAX-044 – Up to USD 1.3 Billion to Back Tumor-Targeted IL-12 Immunotherapy

Regeneron Extends BARDA Agreement With $270 Million Inmazeb Supply Deal for U.S. Ebola Preparedness Through 2031

Regeneron Extends BARDA Agreement With $270 Million Inmazeb Supply Deal for U.S. Ebola Preparedness Through 2031

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
FinanceZGC Shuimu Medical Technology Services

ZGC Shuimu Medtech Raises RMB 100M in Series A+ Round Led by Yijing Capital

COVID-19Innovita Biological Technology

Innovita Biological Technology’s IPO Raises USD 131.3M for POCT Expansion

BiotechLinno Pharmaceuticals

Linno Pharmaceuticals Raises USD 14.78M for Blood-Brain Barrier Drug Delivery Tech

COVID-19Finance

Frontier Biotech Raises USD 51.4M to Advance COVID-19 Drug FB2001

Show More